Journal of Autism and Developmental Disorders

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Modal Labs has secured $750 million in Series D funding at a $15.75 billion valuation, marking a nearly 239% valuation surge in five months as demand for AI inference, GPU cloud infrastructure and autonomous coding agents accelerates, pushing the company's annualized run rate beyond $1 billion. Representative image.

Modal valuation jumps 239% as AI infrastructure demand drives $750m Series D

Salad and Go is coming back after bankruptcy, but competitors bought most of its old drive-thru network

Patient volumes rose 10% at Montrose Regional Health, so why are 77 positions disappearing?

Royal Mail wants 2,500 fewer support roles. Can it afford a frontline retention problem too?

Catalight study challenges ABA dosage norms: Real-world data shows more therapy hours don’t predict better adaptive outcomes

Catalight’s new study challenges ABA dosage guidelines by showing that more therapy hours do not predict better adaptive outcomes. Read what this means.

μFR system
αvβ6-integrin
α4β7 integrin
Þorgerður Katrín Gunnarsdóttir
Zywie Ventures
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynyz
ZYNRELEF

January 18, 2026